Noninvasive Biomarkers of Liver Fibrosis: An Overview

Table 3

AUROC for liver fibrosis biomarkers that are a mix of direct and indirect markers.

Marker	Liver disease evaluated by various markers				AURCO for advanced fibrosis	AURCO for cirrhosis	References
	CHC	CHB	NAFLD	ALD
The Fibrometer	0.892**		0.943	0.83–0.962	0.883–0.962	0.94	[120, 121, 129, 152]
Fibrospect II	0.77–0.831	NA	—	0.83	0.77–0.831		[122, 124, 125]
SHASTA index***	0.878	—	—	—	0.878	—	[126]
Hepascore	0.82			0.83	0.82–0.9	0.89–0.92	[127, 129, 152, 153]
ELF	0.773	0.93–0.98	0.873	0.944	0.773–0.98		[130, 131]^#
		—	—

∗∗mixed population of 337 HCV and 46 HBV patients.
***HVC and HIV co-infected patients.
^#1021 subjects recruited; the numbers in each diagnostic category were as follows: chronic hepatitis C, 496; ALD, 64; fatty liver, 61; hepatitis B, 61; primary biliary cirrhosis or primary sclerosing cholangitis, 53; recurrent disease after liver transplantation, 48; autoimmune hepatitis, 45; hemochromatosis, 32; cryptogenic cirrhosis, 19; hepatitis B and C, 4; 138 patients with other causes of liver disease like granuloma and abnormal liver enzymes from unknown cause.
NA: studied but AUROC is not available.